Abstract
Objective
The cytotoxic effect of berbamine on chronic myeloid leukemia (CML) cell line KU812 was evaluated, and the mechanisms of its action were explored.
Methods
The effect of berbamine on the KU812 cell growth was determined by methyl thiazolyl tetrazolium (MTT) assay. Flow cytometry was used to profile cell cycle alteration upon berbamine treatment. Reverse transcription polymerase chain reaction (RT-PCR) was carried out to determine the transcripts of transforming growth factor-β (TGF-β) receptors (TβRs), Smad3, c-Myc, cyclin D1, p21Cip1(p21), and p27Kip1(p27). Changes in the protein levels of total Smad3, phosphorylated Smad3, the downstream targets of Smad3, and specific apoptosis-related factors were evaluated by Western blotting.
Results
Berbamine inhibited KU812 cell proliferation in a dose- and time-dependent manner, and the half maximal inhibitory concentration (IC50) values for treatments of 24, 48, and 72 h were 5.83, 3.43, and 0.75 μg/ml, respectively. Berbamine induced G1 arrest as well as apoptosis in KU812 cells. Transcriptions of Smad3 and p21 were up-regulated, while those of TβRI, TβRII, c-Myc, cyclin D1 and p27 were not changed significantly. The protein levels of both total Smad3 and phosphorylated Smad3 were both up-regulated after berbamine treatment, together with decreased c-Myc and cyclin D1 and increased p21. Meanwhile, the levels of the anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, were decreased, whereas pro-apoptotic Bax was increased.
Conclusions
Berbamine suppresses KU812 cell proliferation through induction of cell cycle arrest in G1 and apoptosis. It activates Smad3 without additional stimulation of TGF-β, and alters the levels of the Smad3 downstream targets, including c-Myc, cyclin D1 and p21. Our findings suggest that berbamine is a promising drug in the treatment of advanced stage patients with CML.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
An, X., Tiwari, A.K., Sun, Y., Ding, P.R., 2010. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk. Res., 34(10):1255–1268. [doi:10.1016/j.leukres.2010.04.016]
Chaudhury, A., Howe, P.H., 2009. The tale of transforming growth factor-β (TGFβ) signaling: a soigné enigma. IUBMB Life, 61(10):929–939. [doi:10.1002/iub.239]
Claassen, G.F., Hann, S.R., 2000. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor β-induced cell-cycle arrest. PNAS, 97(17):9498–9503. [doi:10.1073/pnas.150006697]
Dong, M., Blobe, G.C., 2006. Role of transforming growth factor-β in hematologic malignancies. Blood, 107(12): 4589–4596. [doi:10.1182/blood-2005-10-4169]
Druker, B.J., Guilhot, F., O’Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., et al., 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med., 355(23):2408–2417. [doi:10.1056/NEJMoa062867]
Elliott, R.L., Blobe, G.C., 2005. Role of transforming growth factor β in human cancer. J. Clin. Oncol., 23(9):2078–2093. [doi:10.1200/JCO.2005.02.047]
Engelman, J.A., Settleman, J., 2008. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev., 18(1):73–79. [doi:10.1016/j.gde.2008.01.004]
Kim, S.J., Letterio, J., 2003. Transforming growth factor-β signaling in normal and malignant hematopoiesis. Leukemia, 17(9):1731–1737. [doi:10.1038/sj.leu.2403069]
Liang, Y., Xu, R.Z., Zhang, L., Zhao, X.Y., 2009. Berbamine, a novel nuclear factor κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Acta Pharmacol. Sin., 30(12):1659–1665. [doi:10.1038/aps.2009.167]
Mitani, K., 2004. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene, 23(24):4263–4269. [doi:10. 1038/sj.onc.1207777]
Ozaki, M., Kanemitsu, N., Yasukawa, M., Fujita, S., 1989. Basophilic crisis of chronic myelogenous leukemia. Jpn J. Med., 28(1):67–71.
Pardali, K., Kowanetz, M., Heldin, C.H., Moustakas, A., 2005. Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1). J. Cell. Physiol., 204(1):260–272. [doi:10.1002/jcp.20304]
Richter, B.W.M., Duckett, C.S., 2000. The IAP proteins: caspase inhibitors and beyond. Sci. STKE, 44:PE1. [doi:10.1126/stke.2000.44.pe1]
Rooke, H.M., Vitas, M.R., Crosier, P.S., Crosier, K.E., 1999. The TGF-β type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia, 13(4):535–541. [doi:10.1038/sj.leu.2401384]
Ruscetti, F.W., Akel, S., Bartelmez, S.H., 2005. Autocrine transforming growth factor-β regulation of hematopoiesis: many outcomes that depend on the context. Oncogene, 24(37):5751–5763. [doi:10.1038/sj.onc.1208921]
Steinberg, M., 2007. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin. Ther., 29(11):2289–2308. [doi:10.1016/j. clinthera.2007.11.005]
Wei, Y.L., Xu, L., Liang, Y., Xu, X.H., Zhao, X.Y., 2009a. Berbanine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacol. Sin., 30(4):451–457. [doi:10.1038/aps.2009.19]
Wei, Y.L., Xu, L., Zhao, X.Y., 2009b. Mechanism related to inhibition of leukemia K562 cells by berbamine. J. Zhejiang Univ. (Med. Sci.), 38(4):387–391 (in Chinese).
Wolfraim, L.A., Fernandez, T.M., Mamura, M., Fuller, W.L., Kumar, R., Cole, D.E., 2004. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N. Engl. J. Med., 351(6): 552–559. [doi:10.1056/NEJMoa031197]
Xu, R.Z., Dong, Q.H., Yu, Y.Z., Zhao, X.Y., Gan, X.X., Wu, D., Lu, Q.H., Xu, X.H., Yu, X.F., 2006. Berbanine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk. Res., 30(1):17–23. [doi:10. 1016/j.leukres.2005.05.023]
Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwano, H., Sugamura, K., Miyazono, K., Mitsuyasu Kato, M., 2002. C-Myc is a downstream target of the Smad pathway. J. Biol. Chem., 277(1):854–861. [doi:10.1074/jbc.M104170200]
Zhang, L., Sun, Z., Shen, A.L., Ma, L., Jiang, X.Y., Ma, G.J., 2003. The effects of the Smad3-knockout on the hematopoiesis of mouse. Chin. J. Biotechnol., 19(4):428–432 (in Chinese).
Zhu, H.J., Burgess, A.W., 2001. Regulation of transforming growth factor-β signaling. Mol. Cell Biol. Res. Commun., 4(6):321–330. [doi:10.1006/mcbr.2001.0301]
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Natural Science Foundation of China (No. 30873095), and the Natural Science Foundation of Zhejiang Province, China (No. 491020-N20529)
Rights and permissions
About this article
Cite this article
Liang, Y., Qiu, X., Xu, Rz. et al. Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity. J. Zhejiang Univ. Sci. B 12, 568–574 (2011). https://doi.org/10.1631/jzus.B1000230
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B1000230